READYCURE, Wins '2025 KHF Innovation Grand Prize
페이지 정보
본문
Dementia Treatment Startup ReadyCure Accelerates Growth through Pre-A Investment,
Project Selection, and MOA Collaboration
-
Proven technological achievements and future potential with 2025 KHF Innovation Grand Prize
-
Strengthened growth foundation through Pre-A investment and selection for global joint research projects
ReadyCure, a startup developing a digital X-ray treatment system dedicated to dementia (CEO: Jung Won-kyu),
is accelerating its growth by securing investment, conducting global joint research, and expanding collaboration with research institutions.
In August, ReadyCure attracted Pre-A investment from JNP MediPartners, a pharmaceutical, biotech, and medical device startup accelerator,
and from Deokin Co., Ltd., a strategic investor specializing in carbon nanotube-based digital X-ray sources.
In particular, JNP MediPartners, a subsidiary of JNP Medi specializing in AI-based clinical trial consulting and solutions,
highly evaluated ReadyCure’s clinical, regulatory capabilities, and growth potential, and thus participated in this investment.
Including this funding, ReadyCure plans to close a total of 1.9 billion KRW in Pre-A investment within this year.
The company has also steadily achieved results in external fundraising.
So far, it has secured over 8.1 billion KRW, including 2.26 billion KRW from private investment and 5.9 billion KRW from national R&D projects.
Following the investment in April by Smart & Growth CEO Hyung In-woo,
this Pre-A investment has provided a stable foundation for continuous growth.
In the research and development field as well, the company has been selected for major projects in succession.
Through the 15 billion KRW Global Cooperative R&D Project by the Ministry of SMEs and Startups,
it is jointly developing the EPATA 1X brain drug delivery platform with the Medical College of Georgia, Augusta University (USA).
Through the 4 billion KRW Bio & Medical Technology Commercialization Project by the Seoul Business Agency,
the company is accelerating clinical and regulatory preparation for its dementia treatment medical device, HeLaXON 1X.
On September 16, it also signed an MOA with the Advanced Radiation Technology Institute of the Korea Atomic Energy Research Institute,
launching the development of technologies and medical devices for treating intractable diseases using low-dose radiation.
Through this agreement, the two sides will pursue practical achievements such as joint research, co-development of commercialization items,
and regular consultative body operations.
ReadyCure’s core technology, HeLaXON, is a digital radiotherapy device that irradiates the brain multi-directionally
with low-energy carbon nanotube-based pulsed beams,
inducing multiple physiological mechanisms such as amyloid-beta (Aβ) and tau protein clearance,
inflammation reduction, and selective blood–brain barrier (BBB) opening.
It is the first dementia-dedicated radiotherapy device developed domestically, recognized for both originality and symbolic significance.
Recent preclinical studies confirmed superior therapeutic efficacy compared to existing dementia drugs,
and in the confirmatory clinical study scheduled for the end of this year,
the company expects to achieve more than 90% suppression of cognitive decline (based on CDR-SB),
which is over three times higher than existing dementia treatments.
Building on these achievements, on September 17 ReadyCure was awarded the Innovation Grand Prize (Korean Hospital Association Award)
at the 2025 KHF Innovation Awards hosted by the Korean Hospital Association,
demonstrating its technological potential and future growth prospects to the public.
By September of this year, ReadyCure plans to complete development of the HeLaXON prototype,
obtain IDE approval from the Ministry of Food and Drug Safety in cooperation with its CRO partner,
and initiate domestic clinical trials within the year.
Going forward, the company intends to accelerate domestic and international regulatory procedures and global market entry,
aiming to lead innovation in the paradigm of dementia treatment.
관련링크
- 이전글Weon Kuu, Chung Participates in ASTRO 2025 25.10.01
- 다음글CEO Weon-Kuu Chung will deliver an oral presentation at ASTRO 2025. 25.07.15
댓글목록
등록된 댓글이 없습니다.
